Circadia Health

Patient monitoring tool

Circadia Health logo
101-200 employees
  • Healthcare
  • B2B
  • Artificial Intelligence
  • MedTech
London, UK

Company mission

To save lives and prevent hospitalisations through early-detection.

Top investors

12% employee growth in 12 months

Our take

On a mission to prevent respiratory failure through early-detection, Circadia Health offers its FDA cleared C100 System, which is a bedtime device that measures respiration rate via radar in adult patients up to four feet away.

The product initially began as a light therapy or sleep tracker device that uniquely combined diagnostics and treatment in one complete system, in order to help users maintain a steady sleep cycle. However, the company expanded its offering during the COVID pandemic. Not only does Circadia’s product act on the third leading cause of death in preventing respiratory failure, but it is also designed for convenience and scalability so it can do so by monitoring patients at home and also play a critical role in helping hospitals combat related illnesses.

Recent funding will be invested in the product, continuing its goal to provide a frictionless solution to clinicians. This will ultimately help improve patient outcomes and reduce the cost of care.

Kirsty headshot

Kirsty

Company Specialist at Welcome to the Jungle

Benefits

  • Private healthcare (inc dental, optical, mental health, physiotherapy & Worldwide cover)
  • 28 days paid leave (inc bank holidays) + flexibility if more needed
  • Pension contributions (3-4%) with Smart Pensions
  • Work from home budget
  • Choice of work laptop and equipment
  • Paid development courses, conferences, learning material
  • Free late meals after 8pm
  • Regular office meals, team events
  • Regular opportunities to California and Karachi offices

Funding (2 rounds)

Jul 2017

$0.3m

CONVERTIBLE

Jun 2017

$100m

CONVERTIBLE

Total funding: $100.3m

This company has top investors

Leadership

Fares Siddiqui

(Co-Founder & CEO)

Previously served as Creative Director for Sultan & Knight, Strategy Analyst for BBOXX, Business Analyst for Voith Group, Health Services Administrator for NHS, and in Plant Operations for Shell.

Dr. Michal Maslik

(Co-Founder & CTO)

Previous experience in Technology Development and Analysis for Bank of America Merrill Lynch. Recently completed PhD in Electrical Engineering Research into Neural Microsystems.